Denali Therapeutics Inc.
AVLAYAH (tividenofusp alfa-eknm)
Hunter Syndrome (MPS II)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for AVLAYAH (tividenofusp alfa-eknm) in Hunter Syndrome (MPS II) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The ongoing global Phase 2/3 COMPASS study is designed to generate confirmatory evidence and support global regulatory submissions for AVLAYAH.”